Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Xcel Energy Inc (XEL) Price & Performance

Abeona Therapeutics IncTrade
Xcel Energy IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Xcel Energy Inc — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while Xcel Energy Inc trades at $78.33 (market cap $48.51B). The key difference: Xcel Energy Inc is far larger — about 115.2× Abeona Therapeutics Inc's market cap, and Xcel Energy Inc pays a 3.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOXEL
Market Cap
$421.19M$48.51B
Sector
HealthUtilities
52-Week High
$7.45$83.91
52-Week Low
$4.17$71.75
Enterprise Value
$276.10M$86.82B
Dividend Yield
3.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Xcel Energy Inc

XEL trades at $78.09, up 1.59% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations in Q2 2026 with EPS of $0.93, driven by infrastructure investments. The company maintains solid fundamentals, including a 15.28% net income margin and a $0.59 quarterly dividend, while analyst consensus is bullish with a $93.80 price target.

Outlook is positive due to strong earnings growth and a $60 billion capital plan supporting future expansion, but risks include regulatory pushback and high debt levels. The stock offers stability with a 2.87% dividend yield, though technical resistance near $79 may limit near-term gains.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Xcel Energy Inc

Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan

Read more on XEL